{
    "nctId": "NCT00849459",
    "briefTitle": "Gene Therapy in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Maximum tolerated dose",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed metastatic adenocarcinoma of the breast\n\n  * Malignant disease in the skin, chest wall, or other sites (lymph nodes or primary tumor in the breast) accessible to percutaneous needle placement and injection\n\n    * Solitary or multiple tumors\n    * Measurable disease in \u2265 2 dimensions by physical examination or CT/MRI scan\n    * Malignant tumors in the skin and chest wall must be \u2265 4 mm in diameter by physical examination\n    * Malignant tumors in other accessible sites must be \u2265 1 cm in diameter on physical examination\n  * Malignant disease in other organs (in addition to skin or chest wall metastases) allowed\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Karnofsky performance status 70-100%\n* Life expectancy \u2265 16 weeks\n* Granulocyte count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9.0 mg/dL\n* PT normal\n* Serum creatinine \u2264 1.5 mg/dL OR creatinine clearance \u2265 45 mL/min\n* Serum total bilirubin \u2264 2.0 times upper limit of normal (ULN)\n* Serum transaminases \u2264 2.5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Weight \u2265 30 kg (for patients treated with the highest dose level of study drug)\n* No active infection or concurrent serious medical illness\n* No HIV positivity\n* No other malignancy within the past 5 years except for the following:\n\n  * Inactive nonmelanoma skin cancer\n  * In situ carcinoma of the cervix\n  * Grade 1 papillary bladder cancer\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n* No anticoagulant therapy with heparin or warfarin for \u2265 2 months after completion of study treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}